Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 226 for:    Inflammatory Myopathies

Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03918356
Recruitment Status : Not yet recruiting
First Posted : April 17, 2019
Last Update Posted : April 19, 2019
Sponsor:
Information provided by (Responsible Party):
Yale University

Brief Summary:
  1. To assess changes in impedance parameters in Idiopathic Inflammatory Myopathies (IIMs).
  2. To assess whether EIM parameters are reflective of disease severity, based on clinical outcome measures of IIMs.

Condition or disease Intervention/treatment Phase
Idiopathic Inflammatory Myopathies Device: electrical impedance myography Other: healthy control group Not Applicable

Detailed Description:
  1. To assess changes in impedance parameters in Idiopathic Inflammatory Myopathies (IIMs) There are structural and compositional changes in muscles, such as edema, adipose infiltration, and/or atrophy, in IIMs. Electrical impedance myography (EIM) is sensitive to such changes. EIM parameters will be different when compared to healthy controls in IIMs.
  2. To assess whether EIM parameters are reflective of disease severity, based on clinical outcome measures of IIMs.

Clinical outcome measures reflect on disease severity which is an indirect measure of muscle involvement in IIMs. If EIM parameters correlate with clinical outcome measure, it would indirectly prove that EIM can reflect disease severity in IIMs


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Application of Electrical Impedance Myography (EIM) to Establish Muscle Impedance Parameters as a Potential Biomarker of Idiopathic Inflammatory Myopathies (IIMs)
Estimated Study Start Date : June 1, 2019
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : June 30, 2021


Arm Intervention/treatment
Experimental: Inclusion Body Myositis patients
Subjects with clinically or clinico-pathologically defined IBM will be included in this study. Patients with consistent clinical and laboratory features including ages 18 to 80 years, duration of symptoms> 12 months, serum creatine kinases (CK) no greater than 15 times upper limit of normal, prominent weakness of quadriceps and/or finger flexor weakness>shoulder abduction weakness along with some characteristic histopathological findings of endomysial inflammatory infiltrate, rimmed vacuoles and protein accumulation or 15-18 nm filaments will be considered as clinically or clinicopathologically defined IBM as proposed by the European Neuromuscular Center (ENMC IBM working group, 2013).
Device: electrical impedance myography
Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.

Experimental: Idiopathic Inflammatory Myopathies patients
Subjects with more than 2 of the following criteria, symmetric proximal weakness, elevated CK, electromyography (EMG) suggesting myositis, muscles biopsy showing inflammatory changes, and typical skin rashes of dermatomyositis (DM) will be recruited as dermatomyositis and polymyositis (DM/PM) based on Bohan and Peter criteria.
Device: electrical impedance myography
Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.

Placebo Comparator: control
Healthy controls without any known neuromuscular disorders and no family history of Amyotrophic lateral sclerosis (ALS) will be recruited for the study.
Other: healthy control group
healthy control




Primary Outcome Measures :
  1. Manual Muscle Testing Score [ Time Frame: 2 years ]
    This scale reflects on muscle strength. It is based on Medical Research Council scale for muscle power, where muscle strength can have a score of 0-5 (0 means no strength and 5 means full strength).Several muscles are examined in Manual Muscle Testing (MMT) and the total strength is reported as the sum of the Medical Research Council (MRC) muscles scale score of each muscles. Total MMT score for this study can range from 0-160, where 0 means no strength in any muscles and 160 means full strength in all the muscles examined.

  2. IBM-Functional rating scale (IBM-FRS) [ Time Frame: 2 years ]
    This scale measure the limitations in daily life from IBM. It ask 10 questions regarding the activities of daily life and each question is scored between 0-4 (Where 4 means no difficulty and 0 means maximum difficulty). Total score can vary from 0-40, and 40 means no limitations in daily life from IBM.

  3. Grip test [ Time Frame: 2 years ]
    A change in grip strength using a Jamar hand dynamometer to assess the grip strength in every participant. Best of three attempts will be used.

  4. Get up and go test [ Time Frame: 2 years ]
    Time will be measured for a participant to stand up from a chair (using arms if necessary), walk 3 meters, turn around, return to the chair, and sit down. The better of two trials will be used.

  5. Six minute walk [ Time Frame: 2 years ]
    Distance walked in 6 minutes will be measured. This has been used as a primary and secondary outcome measures in several clinical trials in various neuromuscular disorders.

  6. Quality of Health and Well Being [ Time Frame: 2 years ]

    Short Form-36 (SF-36) is a measure of the global quality of health and well-being. The SF-36 is an eight-scaled score, which are the weighted sums of the questions in their corresponding section. Each scale can be transformed into a 0-100 scale. Lower score means more disability.

    SF-36 will be scored utilizing a standardized scoring manual. We will obtain a physical component summary scale and a mental component summary scale.


  7. Myositis Intention to Treat Activities Index (MITAX) [ Time Frame: 2 years ]
    MITAX is a scale assessing the extra-muscular disease severity of myositis. It contains 24 questions covering 7 extra muscular organ systems. Each question is scored between 0-4, where 0 = not present, 1= improving, 2= same, 3= worse, and 4= new. This score is then converted to a final score ranging from A-E for each system based on a predefined scoring schema. Total MITAX score can range between 0 to 54.

  8. Physician Global Assessment Score [ Time Frame: 2 years ]
    This is recorded on a 10-cm visual analog scale (VAS) by the physician at the time of evaluation. The score should reflect on the individual's appearance, medical history, physical examination, laboratory testing, and prescribed medical therapy. In this scale 0 means no evidence of disease related damage and 10 means extremely severe damage.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • duration of weakness >12 months.
  • ages 18 to 80 years old.
  • serum CK level no greater than 15 times the upper limit of normal.
  • quadriceps weakness >hip flexor weakness and/or finger flexor weakness >shoulder abduction weakness.
  • one or more of the following pathological findings:
  • endomysial inflammatory infiltrate.
  • rimmed vacuoles.
  • protein accumulation or 15-18 mm filaments.

DM/PM inclusion criteria:

  • ages 18 to 80
  • Symmetric proximal weakness
  • Elevated CK
  • EMG suggestive of myopathy with evidence of muscle membrane irritation
  • Muscle biopsy suggestive of inflammatory myositis (degeneration, regeneration, necrosis, and interstitial mononuclear infiltrates)
  • Typical skin rashes of DM (Heliotrope rash or Gottron sign)

Key inclusion criteria for the control group:

  • no active neuromuscular disorders or known history of neuromuscular disorders.
  • no sign or symptoms of muscle weakness.
  • no family history of muscular dystrophies or ALS.
  • ages 18 to 80

Exclusion Criteria:

  • Patients with decompensated congestive heart failure
  • Patients with chronic kidney disease on hemodialysis
  • Patients with active cancer on chemotherapy or radiotherapy
  • Patients with severe disease who are already wheel chair bound

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03918356


Contacts
Layout table for location contacts
Contact: Joan Nye, BS 203-737-7095 joan.nye@yale.edu

Sponsors and Collaborators
Yale University
Investigators
Layout table for investigator information
Principal Investigator: Bhaskar Roy, MD Yale University

Layout table for additonal information
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT03918356     History of Changes
Other Study ID Numbers: 2000024786
First Posted: April 17, 2019    Key Record Dates
Last Update Posted: April 19, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Diseases
Myositis
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases